Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1992 2
1993 1
1996 2
1997 2
1998 4
1999 7
2000 4
2001 8
2002 6
2003 12
2004 5
2005 19
2006 19
2007 18
2008 27
2009 26
2010 23
2011 21
2012 19
2013 19
2014 33
2015 27
2016 31
2017 27
2018 25
2019 34
2020 44
2021 34
2022 36
2023 32
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Results by year

Filters applied: . Clear all
Page 1
New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. Yahav D, et al. Among authors: tam vh. Clin Microbiol Rev. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33177185 Free PMC article. Review.
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. Tsuji BT, et al. Among authors: tam vh. Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209. Pharmacotherapy. 2019. PMID: 30710469 Free PMC article.
Bill.
Tam V. Tam V. CJEM. 2022 Nov;24(7):786-787. doi: 10.1007/s43678-022-00343-8. Epub 2022 Jul 21. CJEM. 2022. PMID: 35864420 No abstract available.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Abou-Alfa GK, et al. Among authors: tam vc. Future Oncol. 2023 Dec;19(38):2505-2516. doi: 10.2217/fon-2023-0486. Epub 2023 Sep 6. Future Oncol. 2023. PMID: 37671641 Free article. Review.
Toxicity in Patients.
Pogue JM, Tam VH. Pogue JM, et al. Among authors: tam vh. Adv Exp Med Biol. 2019;1145:289-304. doi: 10.1007/978-3-030-16373-0_17. Adv Exp Med Biol. 2019. PMID: 31364083 Review.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: tam vc. Ann Oncol. 2024 Feb 19:S0923-7534(24)00049-8. doi: 10.1016/j.annonc.2024.02.005. Online ahead of print. Ann Oncol. 2024. PMID: 38382875 Free article.
Discussion.
Tam V. Tam V. J Thorac Cardiovasc Surg. 2020 Jan;159(1):262-264. doi: 10.1016/j.jtcvs.2019.06.122. Epub 2019 Oct 6. J Thorac Cardiovasc Surg. 2020. PMID: 31597612 Free article. No abstract available.
507 results